Thoracic Medical Oncologist at Johns Hopkins at Sibley @hopkinskimmel @sibleyonline
Joined February 2013
- Tweets 424
- Following 492
- Followers 966
- Likes 1,867
13 Photos and videos
Susan Combs Scott, MD retweeted
Apr 13
A heartfelt thank you to all of the faculty, sponsors, and attendees for a successful #TexasLung26. We hope to see everyone at #TexasLung27 - April 8-10, 2027 at Austin City Limits for the 5th annual @TLCconference! Save the date!
2
11
81
2,964
Susan Combs Scott, MD retweeted
Kicking off day 2 #Texaslung26 with these powerhouse @WomeninOnc @NarjustFlorezMD @JuliaRotow @SusanScottMD @LeXiuning @KMilehamMD
Biggest take 🏠:
- there is a role for consolidation in stage4
- proactive tox management
- focus on LMD
-we need to celebrate all wins
1
6
18
1,052
Susan Combs Scott, MD retweeted
Apr 10
Our first session is about to begin! Join Dr. @riess_md at 8:30 AM for expert insights on Advanced NSCLC: EGFR, featuring Drs. @SusanScottMD, @JuliaRotow, @ZPiotrowskaMD, Christina Baik, @chulkimMD, @LeXiuning, @jeffyoriomd at #TexasLung26 utm.rocks/tlcagenda?utm_sour…
2
8
440
Susan Combs Scott, MD retweeted
@SusanScottMD breaks down frontline management of EGFR mNSCLC.
For many (though not all) patients, upfront combination “intensification” strategies are becoming the new default.
#TexasLung26
4
12
708
Susan Combs Scott, MD retweeted
EGFR session kicking off with presentations by @SusanScottMD, @JuliaRotow, and @ZPiotrowskaMD ! @TLCconference #TexasLung26
6
17
1,282
Susan Combs Scott, MD retweeted
2
2
52
1,629
Susan Combs Scott, MD retweeted
Mar 16
🔥GAME-CHANGER in 1L EGFR #NSCLC 🫁
#MARIPOSA trial: Amivantamab Lazertinib delivers ~1-YEAR mOS benefit 🚀
✅SubQ Amivantamab ⬇️ infusion reactions visit burden! 💉✨
@lungoncdoc @FawziAbuRous @JuliaRotow
@SusanScottMD #lcsm #OncTwitter
Ep. 1
oncupdates.com/video-podcast…
1
6
12
852
Susan Combs Scott, MD retweeted
Mar 25
🚨Ep. 2 OUT!: Proactive Toxicity Mgmt & CNS Control in #EGFR-Mutant #NSCLC 🧠
👉COCOON regimen ⬇️ grade ≥2 skin toxicity
👉MARIPOSA: 36% vs 18% 3-yr intracranial PFS vs osimertinib
#lcsm #OncTwitter @lungoncdoc @FawziAbuRous @JuliaRotow @SusanScottMD
oncupdates.com/video-podcast…
8
13
790
Susan Combs Scott, MD retweeted
Mar 29
🚨 Ep. 3 OUT NOW! Time Toxicity, CNS Risk & Sequencing Strategy in #EGFRMutant #NSCLC 🧠🫁
👉 MARIPOSA CNS data
👉SubQ amivantamab
⏰Time Toxicity
#lcsm #OncTwitter #Oncology #FOAMed @lungoncdoc @FawziAbuRous @JuliaRotow @SusanScottMD
🎙️Watch full 🗣️👇
oncupdates.com/video-podcast…
2
7
400
Susan Combs Scott, MD retweeted
Day 2 of Winter Lung is officially underway ❄️🫁
No arctic storm in Florida
@SusanScottMD & @JuliaRotow are kicking things off with The EGFR Crossfire: Monotherapy, Intensification, and Beyond
What’s your 1L EGFR choice? ami/laz vs osi/chemo vs osi mono 👇
@gotoPER #WLC26
1
3
7
588
Susan Combs Scott, MD retweeted
Jan 24
Dr. @SusanScottMD makes a strong argument to make osimertinib great again at #WinterLung26.
4
18
2,175
Susan Combs Scott, MD retweeted
17 Dec 2025
Treatment decisions, resistance mechanisms, and the strategies you’ll take straight to clinic. Join moderator Dr. @riess_md and panelists Drs. Christina Baik, @chulkimMD, @LeXiuning, Zofia Piotrowska, @JuliaRotow, @SusanScottMD, and @jeffyoriomd for this power session on Advanced NSCLC: EGFR. We’re offering FREE REGISTRATION for a limited time to the 2-day CE-accredited #TexasLung26. Use promo code FREECME today! na2.hubs.ly/H02BzBh0 #LungCancer #EGFR
4
8
1,274
Susan Combs Scott, MD retweeted
Voting for the @ASCO Election is now open!
I am honored to be running as one of the candidates for the Nominating Committee seat.
Visit asco.org/election to learn more about the candidates and place your vote!
Thank you! 🙏
1
19
61
14,959
Susan Combs Scott, MD retweeted
17 Sep 2025
PALOMA-2 cohort 5: Q4W subcutaneous amivantamab daily lazertinib led to similar efficacy with improved toxicity profile in pts with EGFR-mutant #NSCLC #LCSM
🔸Administration-related reactions in 12%, VTE in 13%
Presented by @SusanScottMD at #WCLC25
ascopost.com/news/september-…
2
7
1,310
Susan Combs Scott, MD retweeted
4 Oct 2025
Dr. @SusanScottMD kicks off session 3 navigating us through the increasingly complex topic of frontline therapy in EGFRm NSCLC at #DCLung25. @HopkinsThoracic @EGFRResisters
5
15
926
Susan Combs Scott, MD retweeted
4 Oct 2025
#DCLung25
@SusanScottMD, an emerging leader in EGFR NSCLC, gives a comprehensive assessment of this space and the key questions:
- FLAURA2 v MARIPOSA 1L
- selection based on clinical subgroups
& biologic subsets (p53 , ctDNA )
@IASLC @HopkinsThoracic #LCSM
4
28
1,695
Susan Combs Scott, MD retweeted
4 Oct 2025
2
21
1,415
Susan Combs Scott, MD retweeted
5 Oct 2025
4 Oct 2025
3
37
4,721
Susan Combs Scott, MD retweeted
4 Oct 2025
#DCLung25
Poignant opening to the DCLung cancer conference by @LAGurwitch on the unseen realities of patients with lung cancer:
- long-term financial impact of treatment
- patient navigation, should be at baseline & beyond
- QOL has improved
@IASLC @OncoAlert #LCSM
4
15
1,674